Prognostic factors and validation of the histologic chronicity score for C3 glomerulopathy: a registry analysis.
C3 glomerulopathy
CKD
anemia
chronicity
prognosis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
14
10
2023
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Data on the prognostic factors for C3 glomerulopathy (C3G) are limited, and validation of the new C3G histologic index (C3G-HI) in different settings is still needed. We aimed to evaluate the chronicity score of C3G-HI and probable prognostic factors in our population. In this registry study, 74 patients from 20 centers with adequate follow-up data were included. Total chronicity score (TCS) was calculated according to percentages of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and presence of arterio- and arteriolosclerosis. Primary composite outcome was defined as doubling of serum creatinine from baseline, undergoing dialysis or transplantation, development of stage 5 chronic kidney disease, or death. Median age was 34 [interquartile range (IQR) 24-46] years, and 39 patients (52.7%) were male. Median follow-up duration was 36 (IQR 12-60) months, and median TCS was 3 (IQR 1-5). Overall, 19 patients (25.7%) experienced primary composite outcome. Multivariate Cox regression model showed that only hemoglobin [adjusted HR (aHR) 0.67, 95% confidence interval 0.46-0.97, Low hemoglobin levels predicted dismal outcomes in patients with C3G. TCS ≥4 was associated with a worse 3-year kidney survival, which validated the 3-year prognostic value of the TCS of C3G-HI in our population.
Sections du résumé
Background
UNASSIGNED
Data on the prognostic factors for C3 glomerulopathy (C3G) are limited, and validation of the new C3G histologic index (C3G-HI) in different settings is still needed. We aimed to evaluate the chronicity score of C3G-HI and probable prognostic factors in our population.
Methods
UNASSIGNED
In this registry study, 74 patients from 20 centers with adequate follow-up data were included. Total chronicity score (TCS) was calculated according to percentages of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and presence of arterio- and arteriolosclerosis. Primary composite outcome was defined as doubling of serum creatinine from baseline, undergoing dialysis or transplantation, development of stage 5 chronic kidney disease, or death.
Results
UNASSIGNED
Median age was 34 [interquartile range (IQR) 24-46] years, and 39 patients (52.7%) were male. Median follow-up duration was 36 (IQR 12-60) months, and median TCS was 3 (IQR 1-5). Overall, 19 patients (25.7%) experienced primary composite outcome. Multivariate Cox regression model showed that only hemoglobin [adjusted HR (aHR) 0.67, 95% confidence interval 0.46-0.97,
Conclusions
UNASSIGNED
Low hemoglobin levels predicted dismal outcomes in patients with C3G. TCS ≥4 was associated with a worse 3-year kidney survival, which validated the 3-year prognostic value of the TCS of C3G-HI in our population.
Identifiants
pubmed: 39421234
doi: 10.1093/ckj/sfae077
pii: sfae077
pmc: PMC11483614
doi:
Types de publication
Journal Article
Langues
eng
Pagination
sfae077Investigateurs
Yasemin Ozluk
(Y)
Ipek Isik Gonul
(II)
Gulistan Gumrukcu
(G)
Cigdem Vural
(C)
Emine Kilinc Gunay
(EK)
Aysel Colak
(A)
Iclal Gurses
(I)
Haci Hasan Esen
(HH)
Ayse Aysim Ozagari
(AA)
Saba Kiremitci
(S)
Handan Kaya
(H)
Cigdem Ozdemir
(C)
Funda Tasli
(F)
Arzu Saglam Ayhan
(AS)
Yasemin Yuyucu Karabulut
(YY)
Neslihan Guney
(N)
Ufuk Usta
(U)
Berna Aytac Vuruskan
(BA)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest. Outside the submitted work, S.M. received support for attending meetings and travel from Amgen and Sanofi Genzyme. N.E. received consulting fees from Sanofi and Takeda, payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Sanofi, Takeda and AstraZeneca, support for attending meetings and travel from Sanofi, Takeda and AstraZeneca, and participated on a data safety monitoring board or advisory board of Takeda. K.T. received payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Takeda and Sanofi Genzyme. The remaining authors have no disclosures. The results presented in this paper have not been published previously in whole or part, except in abstract format.